Development, production and pharmacodynamics of human growth hormone.
With the advent of recombinant DNA technology, it is possible to produce biosynthetic human growth hormone (B-hGH). Novo Nordisk A/S has developed a method for manufacturing B-hGH which is identical to the 22K fraction of pituitary human growth hormone (P-hGH), using a nonpathogenic strain of Escherichia coli as host. B-hGH has been investigated extensively in physical, chemical and biological studies and found to be identical to P-hGH. Pharmacological studies have revealed that B-hGH possesses the same pharmacokinetic and short-term metabolic profiles as P-hGH. Long term clinical studies have shown that B-hGH induces a significant increase in height velocity in children with growth hormone deficiency (GHD) and is characterized by a low antigenicity.
Jørgensen
J T
JT
Medical Department/Growth Factors, Biopharmaceuticals Division, Novo Nordisk A/S, Denmark.
Chirstensen
T
T
Jørgensen
M
M
Jakobsen
G
G
D000818:Animals; D004353:Drug Evaluation, Preclinical; D006130:Growth Disorders / Q000188:drug therapy* / Q000378:metabolism; D013006:Growth Hormone / Q000096:biosynthesis / Q000138:chemical synthesis* / Q000493:pharmacokinetics; D019382:Human Growth Hormone; D006801:Humans; D051381:Rats; D011994:Recombinant Proteins / Q000138:chemical synthesis; D013997:Time Factors
D011994:Recombinant Proteins; D019382:Human Growth Hormone; D013006:Growth Hormone